Mesoblast (ASX:MSB) completed a global private placement to existing US, UK, and Australian shareholders, raising AU$260 million at AU$2.50 per share, according to a Tuesday filing with the Australian bourse.
The proceeds will fund the US commercial launch of Ryoncil for pediatric steroid-refractory acute graft-versus-host disease, accelerate the second phase three study in inflammatory chronic low back pain, expand commercial manufacturing activities, and fund working capital and general corporate purposes, the filing said.
The company's shares fell almost 7% in recent Tuesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。